GB0315291D0 - Assay - Google Patents

Assay

Info

Publication number
GB0315291D0
GB0315291D0 GB0315291A GB0315291A GB0315291D0 GB 0315291 D0 GB0315291 D0 GB 0315291D0 GB 0315291 A GB0315291 A GB 0315291A GB 0315291 A GB0315291 A GB 0315291A GB 0315291 D0 GB0315291 D0 GB 0315291D0
Authority
GB
Grant status
Application
Patent type
Prior art keywords
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0315291A
Other versions
GB2403533A (en )
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORION DIAGNOSTICA OY
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
GB0315291A 2003-06-30 2003-06-30 Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof Withdrawn GB2403533A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0315291A GB2403533A (en) 2003-06-30 2003-06-30 Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB0315291A GB2403533A (en) 2003-06-30 2003-06-30 Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
DK04740371T DK1664769T3 (en) 2003-06-30 2004-06-28 An assay for the detection of prohormones for atrial natriuretic peptide and brain natriuretic peptide in
AT04740371T AT538389T (en) 2003-06-30 2004-06-28 Test for evidence of natriuretic peptide-prohormone of the atrium and brain
US10562081 US8283123B2 (en) 2003-06-30 2004-06-28 Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems
EP20040740371 EP1664769B1 (en) 2003-06-30 2004-06-28 Assay for detecting atrial and brain natriuretic peptide prohormones
PCT/EP2004/006971 WO2005003764A3 (en) 2003-06-30 2004-06-28 Assay for detecting atrial and brain natriuretic peptide prohormones
ES04740371T ES2377122T3 (en) 2003-06-30 2004-06-28 Assay for detecting pheromones natriuretic peptide and brain headphone
CA 2530623 CA2530623C (en) 2003-06-30 2004-06-28 Assay for detecting atrial and brain natriuretic peptide prohormones
PT04740371T PT1664769E (en) 2003-06-30 2004-06-28 Assay for detecting atrial and brain natriuretic peptide prohormones
JP2006518044A JP4741485B2 (en) 2003-06-30 2004-06-28 Detection assays atrial and brain natriuretic peptide prohormones
AU2004254028A AU2004254028B2 (en) 2003-06-30 2004-06-28 Assay
NO20060481A NO20060481A (en) 2003-06-30 2006-01-30 assay
US13633992 US9151766B2 (en) 2003-06-30 2012-10-03 Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems
US14841863 US20160084852A1 (en) 2003-06-30 2015-09-01 Methods of determination of activation or inactivation of atrial natriuretic peptide (anp) and brain natriuretic peptide (bnp) hormonal systems

Publications (2)

Publication Number Publication Date
GB0315291D0 true true GB0315291D0 (en) 2003-08-06
GB2403533A true GB2403533A (en) 2005-01-05

Family

ID=27676371

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0315291A Withdrawn GB2403533A (en) 2003-06-30 2003-06-30 Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof

Country Status (8)

Country Link
US (3) US8283123B2 (en)
EP (1) EP1664769B1 (en)
JP (1) JP4741485B2 (en)
CA (1) CA2530623C (en)
DK (1) DK1664769T3 (en)
ES (1) ES2377122T3 (en)
GB (1) GB2403533A (en)
WO (1) WO2005003764A3 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
WO2007003594A1 (en) * 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Screening methods for inhibitors of the metalloprotease meprin
CN106018820B (en) 2006-08-04 2018-04-27 汉诺威医学院 According tools and methods gdf-15 evaluation of the risk of cardiac intervention
DE602006010705D1 (en) 2006-09-15 2010-01-07 Roche Diagnostics Gmbh Biochemical markers of acute pulmonary embolism
EP2180322A1 (en) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostic biomarkers for the progression of primary chronic kidney disease
EP2370098A4 (en) 2008-12-03 2013-07-17 Morphosys Ag Antibodies for guanylyl cyclase receptors
EP2427764B1 (en) * 2009-05-05 2017-07-26 B.R.A.H.M.S GmbH Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction
JP5362487B2 (en) * 2009-08-27 2013-12-11 塩野義製薬株式会社 proBNP-108 new applications of
US9018168B2 (en) 2010-08-12 2015-04-28 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
US10004754B2 (en) 2014-03-14 2018-06-26 Madeleine Pharmaceuticals Pty Ltd. ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment
WO2014138796A1 (en) * 2013-03-15 2014-09-18 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
WO2017161327A1 (en) * 2016-03-17 2017-09-21 Diazyme Laboratories, Inc. Use of fusion proteins to improve the availability of antigenic peptide epitopes in immunoassays

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212286A (en) * 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
JPS63503309A (en) 1986-05-09 1988-12-02
JPH0570436B2 (en) * 1987-09-01 1993-10-05 Shionogi Seiyaku Kk
JPH0667319B2 (en) 1989-04-19 1994-08-31 塩野義製薬株式会社 Monoclonal antibodies recognizing c end of Anp
DE69032598T2 (en) 1989-06-23 1999-03-11 Genentech Inc Compositions and methods for the synthesis of b-receptor for the natriuretic protein and methods of use
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
JP2665850B2 (en) 1991-11-14 1997-10-22 塩野義製薬株式会社 Recognizing the C-terminus of hBNP monochrome - monoclonal antibody
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
WO1995028952A1 (en) 1992-12-09 1995-11-02 Haemopep Pharma Gmbh Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof
ES2243979T3 (en) 1996-03-04 2005-12-01 Scios Inc. Analysis and reagents for quantifying hBNP.
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
WO2000018422A1 (en) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
DK1698901T3 (en) 1999-01-29 2008-12-08 Roche Diagnostics Gmbh Method for detecting N-terminal proBNP
WO2000071576A3 (en) * 1999-05-24 2001-01-25 Mayo Foundation Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP2001349891A (en) * 2000-04-03 2001-12-21 Unilever Nv Test method and device
US7341838B2 (en) * 2003-04-17 2008-03-11 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
WO2003022028A3 (en) * 2001-09-10 2004-06-24 Meso Scale Technologies Llc Methods, reagents, kits and apparatus for protein function analysis
EP1461616A4 (en) * 2001-11-27 2005-08-10 Diagenics Internat Corp Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
EP1318403B1 (en) * 2001-12-04 2004-07-28 B.R.A.H.M.S Aktiengesellschaft Diagnosis of sepsis determining S100B
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof

Also Published As

Publication number Publication date Type
CA2530623A1 (en) 2005-01-13 application
JP4741485B2 (en) 2011-08-03 grant
GB2403533A (en) 2005-01-05 application
US8283123B2 (en) 2012-10-09 grant
EP1664769B1 (en) 2011-12-21 grant
US9151766B2 (en) 2015-10-06 grant
DK1664769T3 (en) 2012-03-19 grant
ES2377122T3 (en) 2012-03-22 grant
WO2005003764A3 (en) 2006-12-14 application
WO2005003764A2 (en) 2005-01-13 application
JP2007526988A (en) 2007-09-20 application
US20070141634A1 (en) 2007-06-21 application
US20130157311A1 (en) 2013-06-20 application
EP1664769A2 (en) 2006-06-07 application
US20160084852A1 (en) 2016-03-24 application
CA2530623C (en) 2014-09-16 grant

Similar Documents

Publication Publication Date Title
GB0314781D0 (en) Sureclad
DE602004028402D1 (en) Reibelement
DE602004029646D1 (en) Thiolselektive wasserlösliche polymerderivate
DE602004019681D1 (en) Tibiaknieprothese
DE602004024212D1 (en) Chemilumineszenzverbindungen
DE602004015479D1 (en) Ästhetisches endosteales implantat
DE602004027011D1 (en) Uziervorrichtung
GB2403760B (en) Kerbstones
DE602004021472D1 (en) Pyrimiidinverbindungen
DE602004011966D1 (en) Heterocyclylverbindungen
DE602004015972D1 (en) Depigmentierungsmittel
DE602004019446D1 (en) Positionssprengsystem
DE60336086D1 (en) Photodynamisches therapiegerät
DE602004009041D1 (en) Hydroxytetrahydronaphthalenylharnstoffderivate
DE502004009243D1 (en) Spirocyclische cyclohexan-derivate
DE602004020375D1 (en) -system
DE602004026407D1 (en) Histondeacetylase-hemmer
DE602004016390D1 (en) Aromatische triamid-lanthanid-komplexe
DE602004030679D1 (en) Polymerisationsinitiatorsystem
DE602004021117D1 (en) Copolyetherimide

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: ORION DIAGNOSTICA OY

Free format text: FORMER APPLICANT(S): ORION CORPORATION

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)